The U.S. Food and Drug Administration (FDA) greenlighted Roche Holding AG’s experimental therapy to treat a type of advanced blood cancer, nearly a month after the approval of a rival therapy from AbbVie Inc.
Tag Archive for: glofitamab
With Friday’s approval, Epkinly edges out Roche’s bi-specific antibody glofitamab, which is also being proposed for diffuse large B-cell lymphoma.
Roche is dropping its investigational AKT inhibitor ipatasertib, which was being assessed in a Phase III trial for castration-resistant prostate cancer, the company revealed Thursday in its 2022 full-year financial report.